Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Thyroid-associated Ophthalmopathy
Interventions
DRUG

subconjunctival triamcinolone injection

Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.

Trial Locations (1)

120-752

Severance hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT01599273 - Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections | Biotech Hunter | Biotech Hunter